Clinical Trial Update: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a CD19 and CD22 targeted PRIME CAR-T cell therapy in relapsed/refractory B cell lymphoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• PRIME CAR-T cell (CD19 and CD22 targeted) (CD19/CD22 targeted PRIME CAR-T)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN